GHK-Cu: research

A copper-binding skin peptide with small topical studies and untested systemic injections.

Also called: Copper tripeptide-1, Glycyl-L-histidyl-L-lysine copper, Copper-GHK.

Healing and repair peptides · Copper-binding tripeptide complex.

17 human records include secondary reports, mixed products, historical phase 3 news and 1 recruiting trial. No verified systemic injection trial was found.

Studies

GHK-Cu dosage

Typical reported dose: 2 mg once a day at bedtime

  • Venous ulcers: 0.4% cream: 0.4% copper-tripeptide cream once daily, on the skin. Studied in a trial. Studied in: Adults with venous ulcers under standard wound care. (source)
  • Diabetic ulcers: 2% gel: 2% GHK-Cu gel after initial sharp debridement once daily, on the skin. Studied in a trial. Studied in: Adults with diabetic neuropathic ulcers. (source)
  • Facial cream: 12 weeks: GHK-Cu facial cream; strength and amount unavailable twice daily, on the skin. Studied in a trial. Studied in: 71 women with sun-related skin aging. (source)
  • Eye cream: 12 weeks: GHK-Cu eye cream; strength and amount unavailable twice daily, on the skin. Studied in a trial. Studied in: 41 women with sun-related skin aging. (source)
  • Facial cream: chapter report: GHK-Cu facial cream; strength and amount unavailable twice daily, on the skin. Studied in a trial. Studied in: 67 women aged 50–59. (source)
  • Carrier-based facial serum: GHK-Cu lipid-nanocarrier serum; strength and amount not reported twice daily, morning and evening, on the skin. Studied in a trial. Studied in: Women aged 40–65. (source)

Highest studied: 2% gel once daily was used in a diabetic-ulcer trial; scalp exposure is not comparable..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

GHK-Cu side effects and risks

Reported side effects

  • Topical skin reaction: 1/40, 2.5%, stopped in the 8 week serum trial; reacted on both active and comparator sides., mild. Stop the product if irritation persists; the responsible ingredient was uncertain. (source)
  • Darkening after needling plus serum: 8/20, 40%, versus 0/20 with needling alone in a nonrandomized acne scar study., moderate. Stop further application and have new or worsening pigmentation assessed. (source)
  • Injection burning, bumps or bruising: Community reports only; no denominator or reliable incidence., moderate. Persistent, hot or spreading reactions need assessment; do not assume they are normal. (source)
  • Nausea, dizziness or flushing: Reported after injections or blends; no controlled rates and no proven ingredient attribution., moderate. Stop exposure and seek assessment if symptoms persist or worsen. (source)
  • Excess-copper organ injury: A copper toxicity risk; no GHK Cu specific incidence or safe injection threshold is established., serious. Stop and seek urgent care for jaundice, severe vomiting, confusion or reduced urine. (source)
  • Immune reactions to impurities or aggregates: FDA identifies this potential risk for injectable GHK Cu; frequency is unknown., serious. Emergency care for breathing trouble, throat swelling or collapse. (source)

Stop and get help if

  • Trouble breathing, throat swelling or collapse after use: Stop use and call emergency services now.
  • Fever with spreading hot redness, pus or rapidly worsening injection pain: Stop injections and get urgent medical assessment for infection.
  • Severe vomiting, abdominal pain, jaundice, confusion or much less urine: Stop exposure and get urgent care. Bring the product and dose history for possible copper toxicity.

Who should avoid it

  • pregnant: No pregnancy safety data; pregnant people are excluded from the wound trial.
  • breastfeeding: No infant-exposure or breastfeeding safety data; the wound trial excludes breastfeeding.
  • tryingToConceive: Reproductive safety is unknown. The wound trial requires contraception through day 21.
  • under18: No pediatric dosing or safety evidence. The registered wound trial starts at age 18.
  • other: Copper overload can damage the liver and brain. Added copper is unsuitable without specialist direction.
  • other: Avoid after a confirmed allergy to copper-peptide preparations or their ingredients; trial participants with these allergies are excluded.
  • activeCancer: Precaution: it raises growth and blood-vessel signals in cells. Human cancer safety is unknown.
  • cancerHistory: Cancer recurrence risk has not been studied; growth-signal findings warrant review.
  • liverDisease: Copper leaves mainly through bile. Cholestasis or cirrhosis can reduce clearance; GHK-Cu dosing is unstudied.
  • kidneyDisease: Systemic GHK-Cu safety is unstudied. Severe copper toxicity can involve the kidneys.
  • diabetes: Diabetic wounds need infection checks and pressure relief; a cosmetic serum cannot replace wound care.
  • immunosuppressed: Infection and wound-healing risks need review, especially with injections or needling.
  • surgeryPlanned: Discuss use with the procedural team; post-laser benefit was not objectively demonstrated.
  • testedAthlete: Systemic use falls under the inferred S0 unapproved-substance rule; confirm cosmetic use with the anti-doping authority.

Interactions

  • Copper chelators: Added copper conflicts with copper-removal treatment. No direct GHK-Cu interaction study exists.
  • Copper supplements or other copper preparations: These add copper exposure. Safe combined exposure with injected GHK-Cu has not been established.
  • High-dose zinc: Zinc blocks gut copper absorption and excess can cause copper deficiency. It is not a proven safeguard against injected copper.
  • Other peptide blends: Users stack these for repair. Combined safety, compatibility and sterility are not established.
  • Anticoagulants during needling or injections: Needling and injections can bruise or bleed; this is a procedure risk. The acne-scar study excluded anticoagulant users.

Product quality risks

  • FDA identifies peptide impurities and aggregation as potential immune risks for injectable GHK-Cu.
  • Unapproved peptide products may have inaccurate contents or lack sterility; Health Canada and TGA warn about these risks.
  • A purity percentage cannot show the dose per vial, sterility, endotoxin burden or exact copper-binding state.
  • No independent human-use market survey of GHK-Cu vial identity, content and sterility was confirmed.

How GHK-Cu works

The peptide holds copper, a mineral used in repair enzymes. In cells and animals, GHK-Cu changes collagen turnover, inflammation and blood-vessel growth. These effects do not show that injections repair tissue in people.

  • Copper binding: Changes how copper is carried and released; the formulation affects which chemical forms reach tissue.
  • Collagen and matrix turnover: Changes collagen production and the balance of enzymes that rebuild tissue in laboratory studies.
  • VEGF and bFGF growth signals: Increases blood-vessel and cell-growth signals in cultured fibroblasts; clinical effects are uncertain.

Half-life: Human systemic half-life is unknown. Minute-scale estimates are not verified human GHK-Cu pharmacokinetics.

Gaps: No verified human systemic injection trial, dose-finding study, pharmacokinetics or long-term toxicity study was found. A failed topical phase 3 program was reported in 1994, but primary arm-level data and a full trial report were not recovered. Several early cosmetic reports exist only as review summaries or a book chapter; arm strengths and numerical outcomes are missing. GHK-Cu, copper-free GHK, AHK-Cu and undefined copper-peptide mixtures are often confused. Percent serum concentration is not the same as milligrams absorbed or a safe injection dose. No validated human injection maximum exists, so community injection protocols have no numerical studiedMax. No published non-seller clinician dosing guideline for systemic GHK-Cu was verified. Cycle breaks, zinc co-use and blood tests have not been shown to make injections safe. Pregnancy, breastfeeding, fertility, pediatric use, cancer risk and drug interactions lack direct safety studies. EU and UK medicine licensing and local possession/import rules were not fully established. CuHeal remains recruiting without posted results. Skin and hair claims do not establish whole-body repair or longevity.

Related to GHK-Cu

GHK-Cu: the short version

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.